Letifend
Canine leishmaniasis vaccine (recombinant protein)
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Letifend.It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Letifend.
For practical information about using Letifend, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Authorisation details
Product details | |
---|---|
Name |
Letifend
|
Agency product number |
EMEA/V/C/003865
|
Active substance |
Recombinant protein Q from Leishmania infantum MON-1
|
International non-proprietary name (INN) or common name |
Canine leishmaniasis vaccine (recombinant protein)
|
Species |
Dogs
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI07A
|
Publication details | |
---|---|
Marketing-authorisation holder |
LETI Pharma, S.L.U.
|
Revision |
11
|
Date of issue of marketing authorisation valid throughout the European Union |
20/04/2016
|
Contact address |
C/ Del Sol 5 |
Product information
18/02/2022 Letifend - EMEA/V/C/003865 - IB/0027
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
For active immunisation of dogs from 6 months of age to reduce the risk of developing a clinical case of leishmaniasis.